Premium
Paternal Mononuclear Cell Immunization Therapy for Repeated Miscarriage: Predictive Variables for Pregnancy Success
Author(s) -
COWCHOCK F. SUSAN,
SMITH J. BRUCE,
DAVID SAMI,
SCHER JONATHAN,
BATZER FRANCES,
CORSON STEPHEN
Publication year - 1990
Publication title -
american journal of reproductive immunology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.071
H-Index - 97
eISSN - 1600-0897
pISSN - 1046-7408
DOI - 10.1111/j.1600-0897.1990.tb01026.x
Subject(s) - miscarriage , pregnancy , medicine , abortion , relative risk , obstetrics , immunization , gynecology , immunology , antibody , confidence interval , biology , genetics
Pregnancy outcomes for 125 women with unexplained recurrent abortion conceiving after immunologic testing for possible paternal leukocyte immunization were analyzed. Pregnancy success was related to the number of previous miscarriages (relative risk 0.36 for each additional miscarriage after 3), a history of a late pregnancy loss (relative risk 0.18), any other relevant treated or untreatable diagnosis (relative risk 0.27), immunization with paternal mononuclear cells (relative risk 5.6), and time in weeks from test date to LMP of the next pregnancy (relative risk 0.93 for each additional week). The significant difference in pregnancy outcomes between women given a single immunization and nonimmunized women reflected a larger difference between those in each group conceiving within 12 weeks of initiating tests for inclusion in the treatment program. The latter observation suggests that any effect from a single immunization in prevention of recurrent miscarriage is of relatively short duration.